|
293 Companies |
|
491 Products |
|
491 Products |
|
198 Mechanisms of Action |
|
26 Trials |
|
7805 News |
|
| «12...136137138139140141142143144145146...156157» |
- ||||| Cx611 / Takeda
New P1/2 trial: Cx611-0101, eASCs Intravenous Administration to Refractory Rheumatoid Arthritis Patients (clinicaltrials.gov) - Aug 9, 2012
P1/2, N=53, Completed, Sponsor: TiGenix S.A.U.
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: A 3-year Study Following up Patients With Moderate to Severe Rheumatoid Arthritis Treated With Humira in Greece (clinicaltrials.gov) - Aug 9, 2012
P=N/A, N=566, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: Surveillance of Humira Injection in Korean Patients (clinicaltrials.gov) - Aug 9, 2012
P=N/A, N=1779, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Enrolling by invitation --> Completed
- |||||||||| Benlysta (belimumab) / GSK
New P3 trial, Combination therapy: BREVAS: Belimumab in Remission of VASculitis (clinicaltrials.gov) - Aug 9, 2012
P3, N=400, Recruiting, Sponsor: Human Genome Sciences Inc., a GSK Company
- ||| Zinbryta (daclizumab) / Biogen, AbbVie
Enrollment closed, Monotherapy: SELECTED: Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis (clinicaltrials.gov) - Aug 8, 2012
P2, N=600, Active, not recruiting, Sponsor: Biogen Idec
Enrolling by invitation --> Completed Recruiting --> Active, not recruiting
- ||||||| Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J
Trial completion: Study of Subcutaneous Golimumab in Chinese Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy (clinicaltrials.gov) - Aug 8, 2012
P3, N=264, Completed, Sponsor: Centocor, Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||||||||| Actemra SC (tocilizumab SC) / Roche, Halozyme
New P3 trial: A Long-Term Extension Study of WA22762 and NA25220 of Subcutaneous (SC) Tocilizumab (TCZ) in Moderate to Severe Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Aug 8, 2012
P3, N=218, Active, not recruiting, Sponsor: Genentech
- ||| Rebif (human IFN-β-1a) / EMD Serono
Trial completion: Tolerability of Rebif® (Interferon-beta 1-A) Therapy in Korean Patients With Multiple Sclerosis (clinicaltrials.gov) - Aug 7, 2012
P=N/A, N=60, Completed, Sponsor: Merck KGaA
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment change, Combination therapy: A Study of Tocilizumab + DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis (clinicaltrials.gov) - Aug 7, 2012
P3, N=105, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed N=78 --> 105
- ||||| Actemra IV (tocilizumab) / Roche, JW Pharma
New P4 trial, Combination therapy: A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Severe Active Rheumatoid Arthritis, Comparing Tapering Versus Maintaining the Methotrexate Dosage (clinicaltrials.gov) - Aug 7, 2012
P4, N=618, Recruiting, Sponsor: Hoffmann-La Roche
- | New P2 trial: Long Term Treatment Effect of the Safety, Tolerability and Efficacy of AAT in Type 1 Diabetes (clinicaltrials.gov) - Aug 7, 2012
P2, N=24, Active, not recruiting, Sponsor: Rabin Medical Center
- ||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion: TORPEDO Study: A Study on Rapid Effect of Tocilizumab in Patients With Rheumatoid Arthritis With an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) or Anti-TNF (clinicaltrials.gov) - Aug 7, 2012
P3, N=103, Completed, Sponsor: Hoffmann-La Roche
N=78 --> 105 Active, not recruiting --> Completed
- ||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion, Combination therapy: A Study of Tocilizumab + DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis (clinicaltrials.gov) - Aug 7, 2012
P3, N=105, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion: A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura. (clinicaltrials.gov) - Aug 7, 2012
P2, N=124, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Clinical: Monitoring Anticoagulant Therapy in Antiphospholipid Syndrome (clinicaltrials.gov) - Aug 6, 2012
P=N/A, N=150, Recruiting, Sponsor: Johann Wolfgang Goethe University Hospitals
- Trial completion: DIALOG: French Observational Survey to Assess Hypoglycaemia in Insulin-treated Diabetic Patients (clinicaltrials.gov) - Aug 6, 2012
P=N/A, N=4424, Completed, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Recruiting --> Completed
- Trial termination: Minimally Invasive Versus Conventional Approaches in Navigated Total Knee Arthroplasty (TKA) (clinicaltrials.gov) - Aug 5, 2012
P4, N=26, Terminated, Sponsor: Aesculap AG
Recruiting --> Completed Recruiting --> Terminated; Number of patients willing to participate in the study too low
- Enrollment change: Minimally Invasive Versus Conventional Approaches in Navigated Total Knee Arthroplasty (TKA) (clinicaltrials.gov) - Aug 5, 2012
P4, N=26, Terminated, Sponsor: Aesculap AG
Recruiting --> Terminated; Number of patients willing to participate in the study too low N=50 --> 26
- New P4 trial, MRI: Leflunomide Versus Sulfasalazine/Methotrexate in Rheumatoid Arthritis:an Ultrasound/Magnetic Resonance Imaging Study (clinicaltrials.gov) - Aug 5, 2012
P4, N=20, Recruiting, Sponsor: Singapore General Hospital
- | Tysabri (natalizumab) / Biogen, Royalty
New P4 trial: CogMS: Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients (clinicaltrials.gov) - Aug 5, 2012
P4, N=60, Active, not recruiting, Sponsor: Clinique Neuro-Outaouais
- ||| Enrollment closed: Long-term Clinical Effectiveness of the Delta Xtend Reverse Total Shoulder (clinicaltrials.gov) - Aug 5, 2012
P4, N=250, Active, not recruiting, Sponsor: DePuy International
N=50 --> 26 Recruiting --> Active, not recruiting
- ||||| Lantus (insulin glargine) / Sanofi
New P2 trial: Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus on Basal Plus Mealtime Insulin (clinicaltrials.gov) - Aug 5, 2012
P2, N=60, Completed, Sponsor: Sanofi
- || Enrollment closed: MD Logic Pump Advisor -Pediatric Study (clinicaltrials.gov) - Aug 4, 2012
P=N/A, N=80, Active, not recruiting, Sponsor: Rabin Medical Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || Enrollment closed: MD Logic Pump Advisor- Adults Study (clinicaltrials.gov) - Aug 4, 2012
P=N/A, N=135, Active, not recruiting, Sponsor: Rabin Medical Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Avonex (recombinant IFN-β-1a) / Biogen
Trial termination: CHAMPIONS CONT: Controlled High Risk AVONEX® Multiple Sclerosis Prevention Study In Ongoing Neurological Surveillance (clinicaltrials.gov) - Aug 1, 2012
P=N/A, N=383, Terminated, Sponsor: Biogen Idec
Recruiting --> Active, not recruiting Recruiting --> Terminated; low enrollment
- ||||| Avonex (recombinant IFN-β-1a) / Biogen, Zinbryta (daclizumab) / Biogen, AbbVie
Enrollment closed, Monotherapy: Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis (clinicaltrials.gov) - Aug 1, 2012
P3, N=1800, Active, not recruiting, Sponsor: Biogen Idec
Recruiting --> Terminated; low enrollment Recruiting --> Active, not recruiting
- Enrollment change, Combination therapy: FOLVARI: Study of Different Doses of Folic Acid in Combination With Methotrexate in Rheumatoid Arthritis (clinicaltrials.gov) - Jul 31, 2012
P4, N=100, Completed, Sponsor: Postgraduate Institute of Medical Education and Research
Recruiting --> Active, not recruiting N=140 --> 100
- Clinical: IMAGINE-RA: An MRI-guided Treatment Strategy to Prevent Disease Progression in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Jul 31, 2012
P=N/A, N=200, Recruiting, Sponsor: Professor of Rheumatology, MD, DMSci, Kim Horslev-Petersen
- | dalfampridine / Generic mfg.
New P4 trial: FAME - Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra (clinicaltrials.gov) - Jul 31, 2012
P4, N=125, Active, not recruiting, Sponsor: University of Southern Denmark
- Trial completion: DMIRA: Study of Two Different Starting Doses of Methotrexate When Starting Treatment in Rheumatoid Arthritis (clinicaltrials.gov) - Jul 31, 2012
P4, N=100, Completed, Sponsor: Postgraduate Institute of Medical Education and Research
N=140 --> 100 Active, not recruiting --> Completed
- LX 2931 / Lexicon Pharma
Trial completion: A Study to Determine the Safety and Efficacy of LX3305 in Subjects With Active Rheumatoid Arthritis (clinicaltrials.gov) - Jul 31, 2012
P1, N=10, Completed, Sponsor: Lexicon Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- hydrocortisone / Generic mfg.
Trial completion: PHYSCA: Pharmacokinetics of Hydrocortisone After Subcutaneous Administration in Chronic Adrenal Insufficiency (clinicaltrials.gov) - Jul 30, 2012
P2, N=12, Completed, Sponsor: Bruno Allolio
Active, not recruiting --> Completed Not yet recruiting --> Completed
- Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
Trial completion: The Chinese University of Hong Kong Early Arthritis Study (clinicaltrials.gov) - Jul 30, 2012
P=N/A, N=40, Completed, Sponsor: Chinese University of Hong Kong
Not yet recruiting --> Completed Recruiting --> Completed
- Clinical: Effect of High-protein High-fiber Diet in Patients With Autoimmune Hepatitis (clinicaltrials.gov) - Jul 30, 2012
P=N/A, N=40, Recruiting, Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- ||| Actemra IV (tocilizumab) / Roche, JW Pharma
New P3 trial: A Long-Term Extension Study of WA19926 on the Safety of Tocilizumab (RoActemra/Actemra) in Participants With Early Moderate to Severe Rheumatoid Arthritis (clinicaltrials.gov) - Jul 30, 2012
P3, N=15, Active, not recruiting, Sponsor: Hoffmann-La Roche
- ||| Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion: A Study of Duration of Maintained Efficacy in Rheumatoid Arthritis (RA) Patients Off Treatment With MRA(a Development Code of Tocilizumab, an Anti IL-6 Receptor Monoclonal Antibody.) (clinicaltrials.gov) - Jul 30, 2012
P=N/A, N=189, Completed, Sponsor: Chugai Pharmaceutical
Recruiting --> Completed Active, not recruiting --> Completed
- Enbrel (etanercept) / Pfizer, Amgen
Trial completion: RACAT: Rheumatoid Arthritis: Comparison of Active Therapies in Patients With Active Disease Despite Methotrexate Therapy (clinicaltrials.gov) - Jul 30, 2012
P=N/A, N=353, Completed, Sponsor: Department of Veterans Affairs
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||| Plivensia (sirukumab) / J&J
Enrollment open: A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D) (clinicaltrials.gov) - Jul 29, 2012
P3, N=1650, Recruiting, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||| Orencia (abatacept) / BMS
Enrollment open, P4 data: Korean Post-marketing Surveillance for Orencia® (clinicaltrials.gov) - Jul 29, 2012
P=N/A, N=600, Recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | dalfampridine / Generic mfg.
Trial completion: An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS) (clinicaltrials.gov) - Jul 29, 2012
P2, N=20, Completed, Sponsor: Acorda Therapeutics
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | insulin peglispro (LY2605541) / Eli Lilly
New P1 trial: A Study of LY2605541 Versus Insulin Glargine on Blood Sugar (clinicaltrials.gov) - Jul 29, 2012
P1, N=24, Completed, Sponsor: Eli Lilly and Company
- | Basaglar (insulin glargine biosimilar) / Boehringer Ingelheim, Eli Lilly
Trial completion: A Study to Compare LY2963016 to Lantus After a Single Dose to Participants With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Jul 29, 2012
P1, N=20, Completed, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Active, not recruiting --> Completed
- PRT062607 / Biogen, AstraZeneca
New P2 trial: EMBRACE: BIIB057 in Subjects With Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs (clinicaltrials.gov) - Jul 26, 2012
P2, N=0, Withdrawn, Sponsor: Biogen Idec
- Promacta (eltrombopag) / Novartis
New P2 trial: Eltrombopag and High-dose Dexamethasone as First Line Treatment for IT (clinicaltrials.gov) - Jul 26, 2012
P2, N=30, Completed, Sponsor: Hospital Universitario Dr. Jose E. Gonzalez
- | pregabalin / Generic mfg., paroxetine / Generic mfg.
Trial completion: Neuropathic Pain Assessment Comparing Pregabalin and Paroxetine in Management of MS-induced Neuropathic Pain (clinicaltrials.gov) - Jul 25, 2012
P3, N=75, Completed, Sponsor: University of Manitoba
Active, not recruiting --> Completed Recruiting --> Completed
- cyclophosphamide / Generic mfg., cyclosporine / Generic mfg.
Enrollment closed: Cyclophosphamide Plus Cyclosporine in Treatment-Naive Severe Aplastic Anemia (clinicaltrials.gov) - Jul 25, 2012
P1/2, N=22, Active, not recruiting, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting --> Completed Recruiting --> Active, not recruiting
- |||| Artlegia (olokizumab) - R / Pharm
Trial completion: Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy (clinicaltrials.gov) - Jul 25, 2012
P2, N=221, Completed, Sponsor: UCB, Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Cesamet (nabilone) / Bausch Health, Viatris
Trial completion: Efficacy and Safety Evaluation of Nabilone as Adjunctive Therapy to Gabapentin for the Management of Neuropathic Pain in Multiple Sclerosis (clinicaltrials.gov) - Jul 25, 2012
P4, N=50, Completed, Sponsor: University of Manitoba
Active, not recruiting --> Completed Recruiting --> Completed
- Trial completion: MAIVAX: Vaccination Against Influenza in Autoimmune Diseases (clinicaltrials.gov) - Jul 24, 2012
P4, N=234, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
Recruiting --> Completed Active, not recruiting --> Completed
- Enrollment open: Allerdiab: Diagnosis and Physiopathology of Insulin Allergy (clinicaltrials.gov) - Jul 24, 2012
P=N/A, N=70, Recruiting, Sponsor: Assistance Publique - H
Active, not recruiting --> Completed Not yet recruiting --> Recruiting